Trim 30-35% of ISRG at $410-415 to lock in +26% bounce, reduce binary event exposure, maintain residual 20-25% below benchmark
The single decisive 30-35% trim at $410-415 locks in the +26% bounce off $328 while preserving 65-70% of the position to participate in any post-Q3 print rally. The Underweight rating is the decisive move across the Hold boundary that the 10/1 reflection forbids, capturing the asymmetry where the bear case requires only one factor to break (macro persistence, Q3 disappointment, competitive erosion, or multiple compression) while the bull case demands multiple positives aligned (clean beat, guidance raise, da Vinci 5 ramp, competitive irrelevance, 200-SMA reclaim). The 50-SMA stop at $378 preserves the fortress balance sheet floor while reducing binary event exposure. The 10/6 reflection validated the directional Overweight call with +2.7% alpha on the Q2'26 thesis, and the Underweight with residual position and pre-committed re-engagement trigger honors that franchise floor while avoiding the drift-Hold failure mode that produced -3.1% alpha.
| Position | Action |
|---|---|
| Current levels (~$410-415) | Trim 30-35% of existing ISRG exposure |
| Residual position post-trim | Hold at 20-25% below benchmark weight |
| 200-SMA reclaimed ($444.98+) | Trim at $470-480 (initial supply zone) and $500-520 (prior consolidation) per pre-committed zones |
ISRG is fundamentally mispriced by a backward-looking tape while the underlying business is accelerating, with Q3 2026 earnings expected to expose the gap between a 34.2x forward P/E on 39% EPS growth and a stock down 31% from its high.
| Indicator | Value | Signal |
|---|---|---|
| Close | 414.52 | neutral |
| Open | 405.23 | neutral |
| High | 416.81 | neutral |
| Low | 404.20 | neutral |
| Volume | 1,895,430 | neutral |
| 10-EMA | 403.74 | bullish |
| 50-SMA | 383.43 | bullish |
| 200-SMA | 444.98 | bearish |
| RSI(14) | 62.63 | bullish |
| Bollinger Mid | 395.16 | bullish |
| Bollinger Upper | 425.85 | bullish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: 2 of 3: inventory/revenue divergence narrowing, Ion procedure reacceleration, guidance raise
Then: Upgrade to Overweight, retest re-engagement trigger
Business thriving in macro headwind environment with accelerating fundamentals
↩ rebuts: “Bear's 'macro is a headwind' argument”
EV: +15-21% · concedes: Grants the 200-SMA at 444.98 represents overhead supply; Concedes a close below 383.43 would flip medium-term trend bearish; Does not claim ISRG is a permanent monopoly—requires only 3-5 years of pricing power retention on installed base
ISRG is in a confirmed downtrend below its 200-day moving average, with the market pricing in system placement deceleration, macro-driven multiple compression, and growth premium erosion—making the path of least resistance sideways to lower until the 200-SMA at 444.98 is reclaimed on real volume.
· concedes: Q2'26 numbers are solid: 18.5% revenue growth, 33.6% operating margins, $948M FCF — a beautiful quarter; The business is a fortress (fundamental quality is not in question); ISRG's installed base is dominant; J&J Ottava and Medtronic Hugo have been delayed for years; Surgeon training and switching costs provide a real moat; Sell-side estimates have been slow to ratchet down through the drawdown
→ vs conservative: 200-SMA rejection argument is weak—lagging indicator coinciding with 31% drawdown doesn't invalidate reversal; treating it as regime gate is pattern-matching, not analysis
→ vs conservative: Macro bear case (10-year at 2002 highs, 96% odds of no Fed cuts) misses that ISRG's earnings aren't compressing—market under-pricing earnings durability while over-pricing discount rate headwind
→ vs conservative: 1.6% buyback yield comparison to 4.8% risk-free rate ignores compounding effect: buybacks at depressed 414 shrink share count at 34x earnings while business compounds at high-teens; static snapshot analysis
→ vs neutral: Waiting for 200-SMA reclaim at 444.98 with volume confirmation structurally guarantees worse entry—will chase at 460, 480, or 500 as momentum doesn't give comfortable pullbacks; math doesn't work
→ vs neutral: Competitive threat from Medtronic Hugo and J&J Ottava has existed for years with no margin erosion—surgeon training infrastructure, FDA-cleared data, and installed-base flywheel are widening moat empirically
| Bollinger Lower | 364.47 | bearish |
| MACD | 8.06 | bullish |
| Signal | 7.15 | bullish |
| MACD Histogram | +0.91 | bullish |
| ATR(14) | 11.54 | neutral |
| VWMA(20) | ~401.41 | bullish |
Support: 364.47 · 383.43 · 395.16 | Resistance: 425.85 · 444.98 · 448
ISRG technical analysis dated 2026-10-07 shows price at 414.52 with a HOLD rating; short-term (10-EMA 403.74) and medium-term (50-SMA 383.43) trends are bullish but long-term remains bearish below the 200-SMA at 444.98. Key resistance sits at 425.85 (upper Bollinger Band) and 444.98 (200-SMA), with support at 395.16 (Bollinger mid), 383.43 (50-SMA), and 364.47 (Bollinger lower). RSI of 62.63 shows room to run, MACD histogram is expanding positively at +0.91, and VWMA is rising at ~401.41, confirming buyer control. ATR of 11.54 indicates elevated volatility (~2.8% of price), with recommended stops at 395 for tactical longs and 383.43 for invalidating the medium-term uptrend.
Market Cap
$146.44 B
P/E (TTM)
47.5x
Forward P/E
34.2x
PEG Ratio
1.88
Price/Book
8.07x
EPS (TTM)
$8.72
Forward EPS
$12.11
Beta
1.46
52-Week High
$603.88
52-Week Low
$328.57
50-Day Avg
$382.38
200-Day Avg
$445.71
Dividend Yield
0.0%
Revenue (TTM)
$11.03 B
Gross Profit (TTM)
$7.36 B
Gross Margin (TTM)
66.7%
EBITDA (TTM)
$4.18 B
Operating Margin (TTM)
33.6%
Net Income (TTM)
$3.14 B
Net Margin (TTM)
28.4%
Return on Equity (TTM)
17.4%
Return on Assets (TTM)
10.5%
Free Cash Flow (TTM)
$2.62 B
FCF Margin
~23.7%
FCF / Net Income
~83.3%
Cash & ST Investments (Q2'26)
$5.22 B
Total Debt
$0
Current Ratio (Q2'26)
4.96x
Stockholders' Equity (Q2'26)
$18.17 B
Goodwill & Intangibles (Q2'26)
$778.6 M
Inventory (Q2'26)
$2,028.7 M
Diluted Shares (TTM)
357.3 M
Revenue FY2025
$10,064.7 M
Revenue CAGR (FY2022→FY2025)
~17.4%
EPS CAGR (FY2022→FY2025)
~29.2%
FCF CAGR (FY2022→FY2025)
~37.5%
FY2025 Diluted EPS
$7.87
FY2025 Net Income
$2,856.0 M
FY2025 Operating Income
$2,945.5 M
FY2025 Operating Margin
29.3%
FY2025 Buybacks
$2,295.3 M
Q2'26 Revenue
$2,892.3 M
Q2'26 Gross Profit
$1,960.4 M
Q2'26 Operating Income
$971.9 M
Q2'26 Net Income
$818.1 M
Q2'26 Diluted EPS
$2.29
Q2'26 Free Cash Flow
$948.4 M
Q2'26 Operating Cash Flow
$1,061.0 M
R&D (Q2'26)
$370.6 M
Book Value Per Share
$51.34
Strengths
Concerns
Intuitive Surgical is a dominant robotic-surgery platform leader with best-in-class 66.7% gross margins and a razor-and-blade recurring revenue model tied to its growing da Vinci installed base. The company delivered 17.4% revenue CAGR and 29.2% EPS CAGR over FY2022-FY2025, with TTM revenue of $11.03B, net income of $3.14B, and FCF of $2.62B, while maintaining a pristine net-cash balance sheet with $5.22B in cash and zero debt. Despite robust fundamentals and accelerating Q2'26 growth of +18.5% YoY, the stock trades at a rich 47.5x TTM P/E, sits ~31% below its 52-week high, and remains in a technical downtrend below both 50-day and 200-day moving averages, creating a better entry opportunity for patient long-term investors but requiring trend-reversal confirmation before aggressive new position initiation.
Macro: Rates and growth backdrop: 10-year Treasury hit highest level since 2002 (eased slightly but remains elevated); Fed priced at 96% probability for zero rate cuts in 2026 (+1.1pp week-over-week); US recession odds at 6% (down 2.0pp); UK recession odds at 7% (down 2.5pp); Japan recession odds at 4% (flat). S&P 500 and Nasdaq at record highs despite bond weakness. Bitcoin fell below $83,000. Higher rates damaging consumer discretionary more than other sectors. The dominant signal is "higher for longer" with growth slowing but no recession — a regime that historically compresses multiples on quality compounders like ISRG without impairing earnings. ISRG is a long-duration growth name with forward P/E materially above the market.